PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC’s anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin’s Lymphoma (HL), a cancer of the lymphatic system. EMA’s orphan medicinal product designation includes a ten-year period of market exclusivity from the date of approval in the European Union (EU) and allows direct access to a centralized marketing authorization and fee reductions. Resminostat, 4SC’s lead oncologic compound, already received in July 2011 a positive opinion for orphan medicinal product designation in the EU in the indication hepatocellular carcinoma (HCC), the most common type of liver cancer. Furthermore, resminostat recently obtained orphan drug status in the US for HCC and HL..
